RxDoctor Payments Data

Mark Lerman

Nephrology · Dallas, TXNPI 1568440071

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Biomerieux Inc at 32.2% of the total. Reporting peaked in 2019 at $96 and has fallen 84.0% since, to $15 in 2024. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.

$189in general payments, 2019–2025

Across 6 payments — averaging $31.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$61
  • Veloxis Pharmaceuticals, Inc.$49
  • Boston Scientific$44
  • AstraZeneca$18
  • Johnson & Johnson$17
$563,811in research payments, 2019–2025

Across 4 payments — averaging $140,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$564K

What the payments were for

  • Food & beverage$189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$189 in reported general payments places this provider in the 15th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →